Wang Wuyang, Hu Yu, Fu Fangfang, Ren Wu, Wang Tian, Wang Shixuan, Li Yan
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Anv. Wuhan, Wuhan, Hubei, 430030, P.R. China.
Biomark Res. 2024 Oct 29;12(1):129. doi: 10.1186/s40364-024-00673-y.
Uterine sarcoma (US) is a rare malignant tumor that has various pathological types and high heterogeneity in the female reproductive system. Its subtle early symptoms, frequent recurrence, and resistance to radiation and chemotherapy make the prognosis for US patients very poor. Therefore, understanding the molecular mechanisms underlying tumorigenesis and progression is essential for an accurate diagnosis and targeted therapy to improve patient outcomes. Recent advancements in high-throughput molecular sequencing have allowed for a deeper understanding of diseases through multi-omics technologies. In this review, the latest progress and future potential of multi-omics technologies in US research is examined, and their roles in biomarker discovery and their application in the precise diagnosis and treatment of US are highlighted.
子宫肉瘤(US)是一种罕见的恶性肿瘤,在女性生殖系统中具有多种病理类型和高度异质性。其早期症状不明显、复发频繁且对放疗和化疗耐药,使得US患者的预后非常差。因此,了解肿瘤发生和进展的分子机制对于准确诊断和靶向治疗以改善患者预后至关重要。高通量分子测序的最新进展使得通过多组学技术能够更深入地了解疾病。在本综述中,研究了多组学技术在US研究中的最新进展和未来潜力,并强调了它们在生物标志物发现中的作用以及在US精确诊断和治疗中的应用。